

# Katerina V Gurova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2006914/publications.pdf>

Version: 2024-02-01

66  
papers

3,019  
citations

159358

30  
h-index

168136

53  
g-index

71  
all docs

71  
docs citations

71  
times ranked

3625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alkaloid-rich fraction of <i>Ervatamia coronaria</i> sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways. <i>Journal of Ethnopharmacology</i> , 2022, 283, 114666.	2.0	8
2	FACT maintains nucleosomes during transcription and stem cell viability in adult mice. <i>EMBO Reports</i> , 2022, 23, e53684.	2.0	6
3	Can aggressive cancers be identified by the "aggressiveness" of their chromatin?. <i>BioEssays</i> , 2022, , 2100212.	1.2	2
4	Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7248.	1.8	0
5	Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2073-2086.	2.0	8
6	Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. <i>Cell Reports</i> , 2021, 35, 108994.	2.9	21
7	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 4338-4352.	3.2	14
8	Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. <i>International Journal of Cancer</i> , 2020, 146, 1902-1916.	2.3	30
9	Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling. <i>Cancer Prevention Research</i> , 2020, 13, 53-64.	0.7	10
10	The 3D Genome as a Target for Anticancer Therapy. <i>Trends in Molecular Medicine</i> , 2020, 26, 141-149.	3.5	28
11	Histone chaperone FACT is essential to overcome replication stress in mammalian cells. <i>Oncogene</i> , 2020, 39, 5124-5137.	2.6	17
12	Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation. <i>IScience</i> , 2020, 23, 101177.	1.9	10
13	A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks. <i>Journal of Surgical Research</i> , 2020, 251, 126-136.	0.8	1
14	Curaxin CBL0137 has the potential to reverse HIV-1 latency. <i>Journal of Medical Virology</i> , 2019, 91, 1571-1576.	2.5	4
15	The anti-cancer drugs curaxins target spatial genome organization. <i>Nature Communications</i> , 2019, 10, 1441.	5.8	44
16	Chromatin Stability as a Target for Cancer Treatment. <i>BioEssays</i> , 2019, 41, e1800141.	1.2	26
17	Influence of DNA-binding compounds with cancer preventive activity on the mechanisms of gene expression regulation. <i>Uspehi Molekularnoj Onkologii</i> , 2019, 5, 41-63.	0.1	6
18	Histone chaperone FACT and curaxins: effects on genome structure and function. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	10

#	ARTICLE	IF	CITATIONS
19	Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. <i>Cancer Research</i> , 2018, 78, 1431-1443.	0.4	60
20	Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. <i>Science Advances</i> , 2018, 4, eaav2131.	4.7	47
21	TRAIN (Transcription of Repeats Activates INTERferon) in response to chromatin destabilization induced by small molecules in mammalian cells. <i>ELife</i> , 2018, 7, .	2.8	34
22	Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. <i>PLoS ONE</i> , 2018, 13, e0199785.	1.1	26
23	Structure and function of the histone chaperone FACT – Resolving FACTual issues. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2018, 1861, 892-904.	0.9	84
24	Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now141.	0.6	41
25	FACT is a sensor of DNA torsional stress in eukaryotic cells. <i>Nucleic Acids Research</i> , 2017, 45, gkw1366.	6.5	75
26	Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. <i>Frontiers in Microbiology</i> , 2017, 8, 2007.	1.5	28
27	Prognostic value of histone chaperone FACT subunits expression in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 301-311.	1.0	12
28	Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells. <i>Oncotarget</i> , 2017, 8, 20525-20542.	0.8	42
29	Inhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication. <i>Journal of Virology</i> , 2016, 90, 4249-4253.	1.5	21
30	Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. <i>Cancer Research</i> , 2016, 76, 6620-6630.	0.4	20
31	Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 2432-2442.	0.4	62
32	ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin. <i>Cell Cycle</i> , 2016, 15, 455-470.	1.3	2
33	Novel synthetic cyclic integrin $\alpha_5\beta_3$ binding peptide ALOS4: antitumor activity in mouse melanoma models. <i>Oncotarget</i> , 2016, 7, 63549-63560.	0.8	13
34	Small-Molecule Xenomycins Inhibit All Stages of the Plasmodium Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1427-1434.	1.4	11
35	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015, 7, 312ra176.	5.8	120
36	FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency. <i>Journal of Biological Chemistry</i> , 2015, 290, 27297-27310.	1.6	43

#	ARTICLE	IF	CITATIONS
37	Abstract PR09: MYCN and is a therapeutic target in neuroblastoma. , 2015, , .		0
38	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. <i>Blood</i> , 2015, 126, 1391-1391.	0.6	0
39	Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF- $\kappa$ B, and Cell-Cycle Progression in Non- $\mu$ Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2203-2214.	1.9	57
40	Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2014, 5, 11038-11053.	0.8	48
41	Facilitates Chromatin Transcription Complex Is an $\mu$ Accelerator $\mu$ of Tumor Transformation and Potential Marker and Target of Aggressive Cancers. <i>Cell Reports</i> , 2013, 4, 159-173.	2.9	116
42	Curaxin Cbl0137 Demonstrates Significant Antitumor Activity Against Fact-Positive Patient-Derived Pancreatic Ductal Adenocarcinoma. <i>Annals of Oncology</i> , 2013, 24, iv49.	0.6	0
43	Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells. <i>Cell Cycle</i> , 2013, 12, 2423-2434.	1.3	48
44	Targeting FACT Complex Suppresses Mammary Tumorigenesis in <i>Her2<sup>neu</sup></i> Transgenic Mice. <i>Cancer Prevention Research</i> , 2012, 5, 1025-1035.	0.7	52
45	Inflammation and p53: A Tale of Two Stresses. <i>Genes and Cancer</i> , 2011, 2, 503-516.	0.6	156
46	Curaxins: Anticancer Compounds That Simultaneously Suppress NF- $\kappa$ B and Activate p53 by Targeting FACT. <i>Science Translational Medicine</i> , 2011, 3, 95ra74.	5.8	199
47	Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. <i>Oncotarget</i> , 2011, 2, 783-796.	0.8	89
48	Inhibition of Encephalomyocarditis Virus and Poliovirus Replication by Quinacrine: Implications for the Design and Discovery of Novel Antiviral Drugs. <i>Journal of Virology</i> , 2010, 84, 9390-9397.	1.5	34
49	Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. <i>Cell Cycle</i> , 2009, 8, 4155-4167.	1.3	20
50	Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications. <i>Cell Cycle</i> , 2009, 8, 3960-3970.	1.3	52
51	New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. <i>Future Oncology</i> , 2009, 5, 1685-1704.	1.1	211
52	Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. <i>Cancer Research</i> , 2009, 69, 6573-6580.	0.4	100
53	Small-Molecule Inhibitor Which Reactivates p53 in Human T-Cell Leukemia Virus Type 1-Transformed Cells. <i>Journal of Virology</i> , 2008, 82, 8537-8547.	1.5	23
54	p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 10351-10360.	0.4	57

#	ARTICLE	IF	CITATIONS
55	Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. <i>European Journal of Immunology</i> , 2007, 37, 2257-2267.	1.6	27
56	Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. <i>Prostate</i> , 2007, 67, 1801-1815.	1.2	27
57	Small molecules that reactivate p53 in renal cell carcinoma reveal a NF- $\kappa$ B-dependent mechanism of p53 suppression in tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17448-17453.	3.3	257
58	p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism. <i>Cancer Research</i> , 2004, 64, 1951-1958.	0.4	95
59	Paradoxical role of apoptosis in tumor progression. <i>Journal of Cellular Biochemistry</i> , 2003, 88, 128-137.	1.2	44
60	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. <i>Cancer Research</i> , 2003, 63, 2905-12.	0.4	41
61	Apoptosis Inhibitor as a Suppressor of Tumor Progression: Expression of Bcl-2 Eliminates Selective Advantages for p53-Deficient Cells in the Tumor. <i>Cancer Biology and Therapy</i> , 2002, 1, 39-44.	1.5	30
62	Expression of prostate specific antigen (PSA) is negatively regulated by p53. <i>Oncogene</i> , 2002, 21, 153-157.	2.6	45
63	AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. <i>Oncogene</i> , 2002, 21, 3532-3540.	2.6	132
64	Structure and Regulation of the Mouse <i>ing1</i> Gene. <i>Journal of Biological Chemistry</i> , 1999, 274, 32172-32181.	1.6	60
65	Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
66	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8